Selective CB1 cannabinoid receptor antagonist, SR141716A, attenuates liver injury induced by Concanavalin A

Hepatology Research

Volumn 39, Issue 4, 2009, Pages 408-414

  Kojima, Midori ^a   Kato, Naoto ^a   Hirano, Daisuke ^a   Ochi, Takashi ^a   Nii, Aisuke ^a   Shinjo, Katsuhiro ^a   Eda, Hiroyuki ^a,b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Cannabinoid receptor 1; Chemokine; Concanavalin A; Cytokine; Liver injury; SR141716A (rimonabant)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CONCANAVALIN A; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; HEPATITIS; LIVER NECROSIS; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 63649155738     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00473.x     Document Type: Article

References (23)

1. Tiegs G, Hentschel I, Wendel A. A T cell-dependent experimental liver injury in mice inducible by Concanavalin a. J Clin Invest 1992; 90: 196-203.
2. Mizuhara H, O'Neill E, Seki N et al. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med 1994; 179: 1529-37.
3. Takeda K, Hayakawa Y, Kaer LV, Matsuda H, Yagita H, Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc Natl Acad Sci USA 2000; 97: 5498-503.
4. Morita A, Itoh Y, Toyama T et al. Activated Kupffer cells play an important role in intra-hepatic Th1-associated necro-inflammation in Concanavalin A-induced hepatic injury in mice. Hepatol Res 2003; 27: 143-50.
5. + T cells to the liver. Eur J Immunol 2004; 34: 2907-18.
6. Mizuhara H, Uno M, Seki N et al. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology 1996; 23: 1608-15.
7. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 771-84.
8. Klein TW, Newton C, Larsen K et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-96.
9. Siegmund AV, Schwabe RF. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008; 294: G357-62.
10. Lavon I, Sheinin T, Meilin S et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver damage via negative cytokine regulation. Mol Pharmacol 2003; 64: 1334-41.
11. Hegde VL, Hedge S, Cravatt BF, Hofseth LJ, Nagarkatti M, Nagarkatti PS. Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: Involvement of regulatory T cells. Mol Pharmacol 2008; 74: 20-33.
12. 1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (Rimonabant) in rodents. Br J Pharmacol 2003; 140: 115-22.
13. Gary-Bobo M, Elachouri G, Gallas JF et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese zucker fa/fa rats. Hepatology 2007; 46: 122-9.
14. Louis H, Le Moine O, Peny MO et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice. Hepatology 1997; 25: 1382-9.
15. + T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997; 159: 1537-42.
16. Kaneko Y, Harada M, Kawano T et al. Augmentation of Vα14 cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 2000; 191: 105-14.
17. Jaruga B, Hong F, Sun R, Radaeva S, Gao B. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: Up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol 2003; 171: 3233-44.
18. Okamoto S, Yokohama S, Yoneda M, Haneda M, Nakamura K. Macrophage inflammatory protein-1α plays a crucial role in concanavalin A-induced liver injury through induction of proinflammatory cytokines in mice. Hepatol Res 2005; 32: 38-45.
19. Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. Human Mig chemokine: Biochemical and functional characterization. J Exp Med 1995; 182: 1301-14.
20. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 400-11.
21. 2+-induced relaxation in CB1 receptor-deficient mice. Hypertension 2002; 39: 251-7.
22. Jeong WI, Osei-Hyiaman D, Park O et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008; 7: 227-35.
23. Teixeira-Clerc F, Julien B, Gernard P et al. CB1 cannabinoid antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 6: 671-6.